YEM Search

搜索结果

靶点ID:TCMBANKGE008670

靶点别名:PI5P4KA; PIP5K2A; PIP5KII-alpha; PIP5KIIA; PIPK

靶点描述:phosphatidylinositol-5-phosphate 4-kinase type 2 alpha

染色体:10

染色体位置:10p12.2

靶点类型:protein-coding

HERB_ID:HBTAR003012

HGNC_Link:8997

OMIM_Link:603140

Ensembl_Link:ENSG00000150867

靶点对应的植物

ID	拉丁名	药名	药用植物名	功能与主治	来源	药用部位	使用民族

靶点对应的化合物

化合物ID	化合物名	别名	分子式	分子质量	Smiles

TCMBANKIN020961	morin	SMR000058259; C.I. Natural Yellow 8; NCGC00015672-12; KBioGR_002268; 480-16-0; SPBio_000929; 8NFQ3F76WR; 5-18-05-00492 (Beilstein Handbook Reference); NCGC00022214-05; ZINC03881558; BDBM26658; DivK1c_000958; Zlut prirodni 11; NCGC00178000-02; morin ; NCGC00022214-03; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one #; NCI60_001647; NCGC00015672-04; ST50308676; Morin; X1189; MCULE-2387347344; 3,7,2',4'-Pentahydroxyflavone; Zlut prirodni 11 [Czech]; NCGC00015672-09; 2',3,4',5,7-Pentahydroxy-Flavone; AX8140380; C10105; HMS3262K14; NCGC00015672-02; Bio-0589; CTK5B4214; ZX-AT022489; Bois d'arc; NCGC00015672-05; 2',4',5,7-Tetrahydroxyflavonol; 4CH-024478; BRD-K11590034-001-01-0; LMPK12112517; Tox21_500776; NCGC00015672-10; SC-44859; Lopac-M-4008; 2',4',5, 7-Tetrahydroxyflavan-3-ol; A-9317; BC684344; KBio2_004282; BG01594705; Al-Morin; regid855692; C.I. 75660; KBio2_006850; Spectrum_001234; D0NJ4H; C.I. Natural Yellow 11 (VAN); HMS502P20; 3,5 7 2 4-Pentahydroxyflavone; LS-69029; C.I. Natural Yellow 11; Aurantica; EINECS 207-542-9; ZINC3881558; C.I.Natural Yellow 8; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one, 9CI; KBio1_000958; Bois d,Arc; C15H10O7; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; CHEMBL28626; FT-0628989; Morin hydrate; 2',3,4',5,7-pentahydroxy flavone; NSC19801; Aluminum Ionophore I; Spectrum5_000737; DTXSID1022398; 2',4',5,7-Pentahydroxyflavone; UNII-8NFQ3F76WR; 69870_FLUKA; MLS006012034; AC1NQYUY; 3,5,7,2',4'-Pentahydroxyflavone; LP00776; 4H-1-Benzopyran-4-one, 2-2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-; Spectrum4_001924; Toxylon Pomiferum; NCGC00015672-13; Osage Orange; Bois d'arc [French]; AI3-38057; BSPBio_003541; NCGC00015672-08; NCGC00022214-07; ST24039108; BRN 0327474; SR-01000000157-7; Osage Orange Crystals; MLS000069618; GTPL411; KB-220543; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; SBB008853; IDI1_000958; CHEBI:75092; KBio2_001714; KBio3_002824; 2',3,5,7-Pentahydroxyflavone; I14-19447; Osage Orange Extract; 3,5,7,2',4'-Pentahydroxyflavonol; 2',4',3,5,7-Pentahydroxyflavone; MolPort-001-742-584; 2'-Hydroxypelargidenolon 1522; SPECTRUM1502259; AN-23488; NSC-19801; Lopac0_000776; SR-01000000157-2; M-8200; AK111274; Spectrum3_001941; NCGC00178000-01; Aluminum Ionophore I, Selectophore(TM), function tested; AIDS001407; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; KBioSS_001714; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one; cid_5281670; SMP1_000199; M 4008; NCGC00015672-06; Spectrum2_000715; SR-01000000157-6; MFCD00006826; AJ-46640; NCGC00022214-06; NSC 19801; I14-114104; SCHEMBL19984; 2',3,4',5,7-Pentahydroxyflavone; CCRIS 8680; ACon1_000260; 4H-1-Benzopyran-4-one, 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-; NCGC00015672-07; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-1-benzopyran-4-one; MEGxp0_001864; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4-chromenone; 4H-1-Benzopyran-4-one, 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-,monohydrate; NCGC00022214-04; EU-0100776; NCGC00261461-01; P0041; Flavone,3,4',5,7-pentahydroxy-; 91A9D69E-FAB0-45CD-90E5-DEEFBADE86C1; HMS1921P12; AIDS-001407; NCGC00015672-11; BIDD:ER0115; 2',4',5,7-Tetrahydroxyflavan-3-ol; Bois d'Arc; 11128-85-1; AKOS001582671; NINDS_000958; NCGC00015672-03; Flavone, 2',3,4',5,7-pentahydroxy-; Calico Yellow; 2',5,7-Tetrahydroxyflavan-3-ol; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; SDCCGMLS-0003296.P003; CCG-39036; NCGC00015672-14; NCGC00015672-01; SR-01000000157; Morin, p.a., 97.0%; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromone; MORIN, REAG; YXOLAZRVSSWPPT-UHFFFAOYSA-N	C15H10O7	302.24	C1=CC(=C(C=C1O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O
TCMBANKIN055948	Eupachlorin acetate	enoxaparin;nadroparin	C22H27ClO8	420.453	[C@]12([H])[C@](O[H])(C(C([H])([H])[H])=C([H])[C@@]1([H])OC(=O)C([H])([H])[H])[C@]3([H])[C@]([H])(C(=C([H])[H])C(=O)O3)[C@]([H])(OC(=O)\C(\C([H])([H])[H])=C([H])/C([H])([H])[H])C([H])([H])[C@]2(O[H])C ([H])([H])Cl
TCMBANKIN058964	heparin	enoxaparin;nadroparin	C26H42N2O37S5	1134.9 g/mol	CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O
TCMBANKIN060889	delta(9)-tetrahydrocannabinol		C21H30O2	314.5 g/mol	CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O
TCMBANKIN060892	tetrahydrocannabinol delta8				CCCCCC1=CC2=C(C3C=C(CCC3C(O2)(C)C)C)C(=C1)O

靶点对应的疾病

疾病ID	疾病名	MeSH名	HPO名	UMLS名	疾病类型

TCMBANKDI002974		Neoplasms	-	Neoplastic Process	disease
TCMBANKDI007737		Pathological Conditions, Signs and Symptoms; Neoplasms	-	Neoplastic Process	disease
TCMBANKDI010792		Mental Disorders	-	Mental or Behavioral Dysfunction	disease
TCMBANKDI013495		Hemic and Lymphatic Diseases	Neoplasm; Abnormality of blood and blood-forming tissues	Neoplastic Process	group
TCMBANKDI015485		Mental Disorders	Abnormality of the nervous system	Mental or Behavioral Dysfunction	disease
TCMBANKDI016700		Mental Disorders	-	Mental or Behavioral Dysfunction	disease
TCMBANKDI025632		Mental Disorders	-	Mental or Behavioral Dysfunction	disease